Sign In
Buy KLRA
Kailera Therapeutics Stock Insider Power
Based on the 73 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 232.94M and sold 93.71M KLRA shares in the last 73 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.
Insider Power
|
100.00 |
| ● Buy | 232.94M shares |
| ● Sell | 93.71M shares |
|
86% Buy Activity
Negligible or No Correlation
|
|
No Significant SignalsNo statistically significant buy or sell signals detected in recent insider data. |
|
Historical Insider Trades
| Date | Type | Person | Role | Amount |
|---|---|---|---|---|
|
Apr 20, 2026 Buy |
Bain Capital Investors Llc 10 Percent Owner |
8 398 438 Value: $0.13B |
||
|
Apr 16, 2026 Buy |
Koppel Adam |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Kaplan Andrew T. |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Cloghessy Paula Chief People Officer |
60 000 Value: $960.0K |
||
|
Apr 16, 2026 Buy |
Akamine Scott Chief Legal Officer |
60 000 Value: $960.0K |
||
|
Apr 16, 2026 Buy |
Renaud Ronald C Jr CEO & President |
300 000 Value: $4.80M |
||
|
Apr 16, 2026 Buy |
Burgess Paul D. See Remarks |
100 000 Value: $1.60M |
||
|
Apr 16, 2026 Buy |
Milligan John F Director |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Coleman Jamie Beth Chief Commercial Officer |
75 000 Value: $1.20M |
||
|
Apr 16, 2026 Buy |
Mackay Martin Director |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Wasserman Scott M. Chief Medical Officer |
100 000 Value: $1.60M |
||
|
Apr 16, 2026 Buy |
Hite Christopher Director |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Clyburn Frank Director |
38 300 Value: $612.8K |
||
|
Apr 16, 2026 Buy |
Pagan Douglas W. Chief Financial Officer |
100 000 Value: $1.60M |
||
|
Apr 16, 2026 Buy |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10 Percent Owner |
2 034 133 Value: $37.7M |
||
|
Apr 16, 2026 Buy |
Koppel Adam |
16 875 000 Value: $0.31B |
||
|
Apr 16, 2026 Buy |
Koppel Adam |
4 145 768 Value: $76.9M |
||
|
Apr 16, 2026 Buy |
Bain Capital Investors Llc 10 Percent Owner |
17 857 143 Value: $0.33B |
||
|
Apr 16, 2026 Buy |
Bain Capital Life Sciences Investors, Llc 10 Percent Owner |
16 875 000 Value: $0.31B |
||
|
Apr 16, 2026 Buy |
Bain Capital Life Sciences Investors, Llc 10 Percent Owner |
4 145 768 Value: $76.9M |
||
|
Apr 16, 2026 Buy |
Kaplan Andrew T. |
17 857 143 Value: $0.33B |
||
|
Apr 16, 2026 Buy |
Burgess Paul D. See Remarks |
191 444 Value: $1.01M |
||
|
Apr 16, 2026 Buy |
Burgess Paul D. See Remarks |
325 491 Value: $2.36M |
||
|
Apr 16, 2026 Buy |
Wasserman Scott M. Chief Medical Officer |
427 960 Value: $2.25M |
||
|
Apr 16, 2026 Buy |
Wasserman Scott M. Chief Medical Officer |
147 324 Value: $1.07M |
About Insider Power
Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.
It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.
While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.
* October 6th, 2025 - Tested on 5562 stocks
